TITLE:
Application and Research Advancement of Antibody-Conjugated Drugs in Non-Small Cell Lung Cancer
AUTHORS:
Binting Huang, Kaifang Li, Xiangsheng Wu, Fuyi Zhang, Yepeng Li
KEYWORDS:
Non-Small Cell Lung Cancer, Antibody Coupling Drugs, Combination Therapy, Adverse Reaction
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.13 No.1,
January
16,
2025
ABSTRACT: Lung cancer is one of the malignant tumor diseases with high morbidity and high mortality in the world. Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Currently, chemotherapy, targeted therapy, immunotherapy or combination therapy is the main treatment for NSCLC, but it is still inevitably faced with the challenges of acquired drug resistance and tumor progression. The birth of antibody conjugator provides a new choice for its treatment. Antibody conjugator is a new type of biotherapeutic drug which is connected by monoclonal antibody via linker and cytotoxic drug. It has the characteristics of precision, high efficiency and low toxicity, etc. In recent years, its research and development and clinical trials have been endless. It shows that this new type of drug has great potential in the field of tumor therapy. In this paper, the structural characteristics, mechanism of action, current application, research achievements, challenges, countermeasures and development of ADC in NSCLC treatment are reviewed.